RSA 329:1 · Practice

Source history

• 1915, 167:1. PL 204:1. RL 250:1. RSA 329:1
• 1959, 144:1
• 1981, 396:1
• 1997, 214:2, eff. June 18, 1997

Related materials

Bill relationships

• 2026 HB1292 reference · effective 2027-01-01

  stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a. “Qualifying

• 2026 HB1292 reference · effective 2027-01-01

  withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi

• 2026 HB1292-FN reference · effective 2027-01-01

  withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi

• 2026 HB1292-FN reference · effective 2027-01-01

  stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a. “Qualifying

• 2026 HB1321 amend

  ravenous therapy. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Subdivision; Provision of Elective Intravenous Therapy. Amend RSA 329 by inserting after section 53 the following new subdivision: Provision of Elective Intravenous Therapy 329:54 Definitions. As used in this subdivision, "elective intravenous therapy" means a procedure: I. To admin

• 2026 HB1335 amend · effective 2027-01-01

  use of Representatives in General Court convened: 1 New Subdivision; Physicians and Surgeons; Disclosure of Preferential Promotion Received by Provider; When Required. Amend RSA 329 by inserting after section 53 the following new subdivision: Disclosure of Preferential Promotion 329:54 Definitions. In this subdivision: (a) “Preferential promotion” means any financial arrangement, incentiv

• 2026 HB1562 reference · effective 2032-01-01

  to examine the impact of direct pay models on the health care system of New Hampshire, with special attention given to the impact of implementation of the direct primary care law, RSA 329:1-e and 2019, 330 (HB 508). The department shall provide the results of the study to the speaker of the house of representatives, the senate president, the house clerk, and the senate clerk, on or before June 30, 2027. 6

• 2026 HB1562-FN reference · effective 2032-01-01

  to examine the impact of direct pay models on the health care system of New Hampshire, with special attention given to the impact of implementation of the direct primary care law, RSA 329:1-e and 2019, 330 (HB 508). The department shall provide the results of the study to the speaker of the house of representatives, the senate president, the house clerk, and the senate clerk, on or before June 30, 2027. 6

• 2026 HB1702 amend

  seeking chemical abortions that it may be possible to undo the effects of mifepristone, a drug commonly used to induce abortions. 2 New Subdivision; Chemical Abortion. Amend RSA 329 by inserting after section 53 the following new subdivision: Chemical Abortion 329:54 Definitions. In this subdivision: I. "Chemical abortion" or "medical abortion" means the use or prescription of any drug or

• 2026 HB1702-FN amend

  seeking chemical abortions that it may be possible to undo the effects of mifepristone, a drug commonly used to induce abortions. 2 New Subdivision; Chemical Abortion. Amend RSA 329 by inserting after section 53 the following new subdivision: Chemical Abortion 329:54 Definitions. In this subdivision: I. "Chemical abortion" or "medical abortion" means the use or prescription of any drug or

• 2026 HB1735 reference

  stitutional Review Board; and (b) "Off-label use" means prescribing an FDA approved drug, biologic, or device for a use not approved for that specific indication consistent with RSA 329:17, VI-b. III. "Physician" means the licensed allopathic or osteopathic physician who is providing medical care or treatment to the[ eligible] patient for the terminal or qualifying severe illness. III-a.(a) “Quali

• 2026 HB1735 reference

  withstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to [an eligible] a patient regarding or prescription for or treatment with [an investigational] a drug, biologic, or device pursuant to this chapter. II. Notwithstandi

Opinions and discipline decisions mentioning this RSA

• 2025 N.H. 13, Appeal of Doe (Bd. of Med.) Supreme Court opinion · March 18, 2025
• 2015-0412, N.C. v. New Hampshire Board of Psychologists; New Hampshire Board of Psychologists v. Alethea E. Young, Ph.D. Supreme Court opinion · September 20, 2016